Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega-scale single cell analysis with improved efficiency and ease of use.

GEM-X is exclusively available for use on its Chromium X Series instruments, 10x Genomics added. More on 10x Genomics 10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript ...

This collaboration will use 10x Genomics' Chromium GEM-X technology for single-cell analysis. Launched in 2024, the GEM-X technology architecture delivers superior sensitivity, throughput ...

CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...

Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the life science tools and diagnostics group to be down ...

Wall Street analysts expect 10x Genomics (TXG) to post quarterly loss of $0.32 per share in its upcoming report, which indicates a year-over-year increase of 22%. Revenues are expected to be $158. ...

Coupled with the invalidation of 10x Genomics' 10,155,981 patent last year, Parse has now invalidated all claims that 10x Genomics asserts against Parse products, further reinforcing Parse's ...